Impact of Medical Information Science on Drug Discovery and Pharmaceutical Data Management
DOI:
https://doi.org/10.56294/mw2024516Keywords:
Medical Information Science, Drug Discovery, Artificial Intelligence, Machine Learning, Big Data Analytics, Predictive ModelingAbstract
Having a significant impact on drug discovery, clinical study administration, and pharmaceutical data management, medical information science has grown to be a main player in the pharmaceutical industry. Combining Artificial Intelligence (AI), Machine Learning (ML), Big Data Analytics, Natural Language Processing (NLP), Blockchain, and Cloud Computing has sped, more accurate, less expensively revolutionised the way things are done. Computational drug design and genomics have hastened molecular screening and target selection; predictive modelling based on artificial intelligence has made testing how well medications function simpler. Finding new patients, customising medications, and monitoring pharmaceuticals after they have been sold have all become simpler using Electronic Health Records (EHRs) and Real-World Data (RWD). Using virtual screening techniques and high-throughput screening (HTS) has accelerated the search for novel medications and rendered traditional testing procedures less relevant. Blockchain technology simultaneously ensures accurate data, adherence to rules, and safe pharmaceutical operations as well as precise legislation. Big challenges include artificial intelligence model bias, data privacy concerns, complex rules, and systems unable to interact with one another still exist even with these developments. We must establish moral guidelines, open artificial intelligence systems, and uniform standards if we are to address these issues. Future pharmaceutical research will be much improved by synthetic biology, deep learning, and quantum computing. This will improve patient outcomes and hasten the development of fresh medications. This paper demonstrates the significance of Medical Information Science to modern medications as well as how it may inspire fresh ideas in healthcare worldwide.
References
1. Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today 2021, 26, 80–93.
2. Xu, Y.; Liu, X.; Cao, X.; Huang, C.; Liu, E.; Qian, S.; Liu, X.; Wu, Y.; Dong, F.; Qiu, C.W.; et al. Artificial intelligence: A powerful paradigm for scientific research. Innovation 2021, 2, 100179.
3. Zhuang, D.; Ibrahim, A.K. Deep learning for drug discovery: A study of identifying high efficacy drug compounds using a cascade transfer learning approach. Appl. Sci. 2021, 11, 7772.
4. Pu, L.; Naderi, M.; Liu, T.; Wu, H.C.; Mukhopadhyay, S.; Brylinski, M. EToxPred: A machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacol. Toxicol. 2019, 20, 2.
5. Rees, C. The Ethics of Artificial Intelligence. In IFIP Advances in Information and Communication Technology, 1st ed.; Chapman and Hall/CRC; CRC Press/Taylor & Francis Group: Boca Raton, FL, USA, 2020; Volume 555, pp. 55–69. ISBN 9781351251389.
6. Wess, G.; Urmann, M.; Sickenberger, B. Medicinal Chemistry: Challenges and Opportunities. Angew. Chem. Int. Ed. 2001, 40, 3341–3350.
7. Gómez-Bombarelli, R.; Wei, J.N.; Duvenaud, D.; Hernández-Lobato, J.M.; Sánchez-Lengeling, B.; Sheberla, D.; Aguilera-Iparraguirre, J.; Hirzel, T.D.; Adams, R.P.; Aspuru-Guzik, A. Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules. ACS Central Sci. 2018, 4, 268–276.
8. Hansen, K.; Biegler, F.; Ramakrishnan, R.; Pronobis, W.; Von Lilienfeld, O.A.; Müller, K.R.; Tkatchenko, A. Machine learning predictions of molecular properties: Accurate many-body potentials and nonlocality in chemical space. J. Phys. Chem. Lett. 2015, 6, 2326–2331.
9. Gawehn, E.; Hiss, J.A.; Schneider, G. Deep Learning in Drug Discovery. Mol. Inform. 2016, 35, 3–14.
10. Lysenko, A.; Sharma, A.; Boroevich, K.A.; Tsunoda, T. An integrative machine learning approach for prediction of toxicity-related drug safety. Life Sci. Alliance 2018, 1, e201800098.
11. You, J.; McLeod, R.D.; Hu, P. Predicting drug-target interaction network using deep learning model. Comput. Biol. Chem. 2019, 80, 90–101.
12. Liu, X.; IJzerman, A.P.; van Westen, G.J.P. Computational Approaches for De Novo Drug Design: Past, Present, and Future. In Methods in Molecular Biology; Humana Press Inc.: Totowa, NJ, USA, 2021; Volume 2190, pp. 139–165.
13. Bannigan, P.; Aldeghi, M.; Bao, Z.; Häse, F.; Aspuru-Guzik, A.; Allen, C. Machine learning directed drug formulation development. Adv. Drug Deliv. Rev. 2021, 175, 113806.
14. Santín, E.P.; Solana, R.R.; García, M.G.; Suárez, M.D.M.G.; Díaz, G.D.B.; Cabal, M.D.C.; Rojas, J.M.M.; Sánchez, J.I.L. Toxicity prediction based on artificial intelligence: A multidisciplinary overview. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2021, 11, e1516.
15. J Satpathy, B B Mohtra. (2015). Peep into Behaviourial Science of Choice. International Journal on Research and Development - A Management Review, 4(4), 61 - 68.
16. Nussinov, R.; Zhang, M.; Liu, Y.; Jang, H. AlphaFold, Artificial Intelligence (AI), and Allostery. J. Phys. Chem. B 2022, 126, 6372–6383.
17. Bai, Q.; Liu, S.; Tian, Y.; Xu, T.; Banegas-Luna, A.J.; Pérez-Sánchez, H.; Huang, J.; Liu, H.; Yao, X. Application advances of deep learning methods for de novo drug design and molecular dynamics simulation. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2022, 12, e1581.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
